Teva: Biosimilars In The US Will Become Like Complex Generics

North America Head Brendan O’Grady Discusses Teva’s Biosimilar Expectations

 
• By Dean Rudge
  
Brendan O'Grady Teva
Teva has a "very nice current balance between our own internal projects and our partnerships without a lot of overlap." • Source: Teva
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products